AZ-23

AZ-23 is an inhibitor of RET and FLT3 and related targets used in studies of MAPK / ERK Signaling and JAK-STAT Signaling. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-responsive transcriptional signaling and immune regulation in cancer, cell signaling, and neuroscience models.

By inhibiting RET and FLT3 and related targets, AZ-23 can be used to examine mitogenic kinase cascades, proliferation control, and differentiation-linked signaling and cytokine-responsive transcriptional signaling and immune regulation. The kinase annotation adds relevance to biochemical kinase assays, phospho-signaling studies, and selectivity profiling, together with downstream-response mapping in the same experimental setting. In cancer, cell signaling, and neuroscience models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving RET and FLT3 and related targets
• Pathway perturbation studies connected to MAPK / ERK Signaling and JAK-STAT Signaling
• Concentration-response inhibition and target-dependence studies
• Biochemical kinase assays, phospho-signaling studies, and selectivity profiling

Overall, AZ-23 is appropriate when a defined chemical perturbant is needed to connect RET and FLT3 and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer, cell signaling, and neuroscience models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.